论文部分内容阅读
目的探讨凉润通络方对糖尿病大鼠胃肠运动功能改善的机制。方法雄性Wistar大鼠随机共分为凉润通络组、西沙必利组、模型组、正常组,每组又分3个治疗阶段,即预防阶段、早期治疗阶段、治疗阶段。采用链脲佐菌素(STZ)注射制作糖尿病大鼠模型,造模成功后,不予降糖药控制血糖,分别饲养6周、12周和18周后,各组再给予灌胃治疗。灌胃6周后检测血浆中的胃动素(MOT)、胆囊收缩素(CCK)、生长抑素(SS)、血糖、体重。结果糖尿病模型组大鼠不同阶段血浆中的MOT和CCK含量随着时间的延长均逐渐升高,SS血浆含量和体重则逐渐降低。与模型组比较,凉润通络方组在3个阶段对MOT、CCK、SS及体重均有明显改善(P<0.05),而西沙必利组对SS及后两个阶段的体重无明显改善(P>0.05)。两组各阶段对血糖均无明显影响(P>0.05)。结论凉润通络方在改善糖尿病大鼠胃肠功能障碍方面具有优势。
Objective To investigate the mechanism of Liangrun Tongluo Recipe in improving gastrointestinal motility in diabetic rats. Methods Male Wistar rats were randomly divided into two groups: Liangrun Tongluo group, cisapride group, model group and normal group. Each group was divided into three treatment phases: prevention phase, early treatment phase and treatment phase. Diabetic rats were injected with streptozotocin (STZ). After successful modeling, blood glucose was not controlled by hypoglycaemic agents. After 6 weeks, 12 weeks and 18 weeks of feeding, the rats in each group were given gavage. Plasma concentrations of motilin, cholecystokinin (CCK), somatostatin (SS), blood glucose and body weight were measured 6 weeks after gavage. Results The levels of MOT and CCK in plasma increased gradually with the increase of time in diabetic model rats, and the plasma levels of SS and weight gradually decreased. Compared with the model group, the patients in Liangrun Tongluo Decoction group had a significant improvement in MOT, CCK, SS and body weight in three stages (P <0.05), while the cisapride group had no significant improvement in body weight in SS and the latter two stages (P> 0.05). The two groups had no significant effect on blood glucose (P> 0.05). Conclusion Liangrun Tongluo Prescription has an advantage in improving gastrointestinal dysfunction in diabetic rats.